Suppr超能文献

硫代硫酸钠可减轻血管紧张素 II 诱导的高血压、蛋白尿和肾损伤。

Sodium thiosulfate attenuates angiotensin II-induced hypertension, proteinuria and renal damage.

作者信息

Snijder Pauline M, Frenay Anne-Roos S, Koning Anne M, Bachtler Matthias, Pasch Andreas, Kwakernaak Arjan J, van den Berg Else, Bos Eelke M, Hillebrands Jan-Luuk, Navis Gerjan, Leuvenink Henri G D, van Goor Harry

机构信息

Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

出版信息

Nitric Oxide. 2014 Nov 15;42:87-98. doi: 10.1016/j.niox.2014.10.002. Epub 2014 Oct 16.

Abstract

Hypertension and proteinuria are important mediators of renal damage. Despite therapeutic interventions, the number of patients with end stage renal disease steadily increases. Hydrogen sulfide (H(2)S) is an endogenously produced gasotransmitter with vasodilatory, anti-inflammatory and antioxidant properties. These beneficial characteristics make H(2)S an attractive candidate for pharmacological use in hypertensive renal disease. We investigated the protective properties of H(2)S in angiotensin II (Ang II)-induced hypertensive renal disease in rats. Treatment with the H(2)S donor NaHS and major H(2)S metabolite sodium thiosulfate (STS) during three weeks of Ang II infusion reduced hypertension, proteinuria, oxidative stress and renal functional and structural deterioration. In an ex vivo isolated perfused kidney setup, NaHS, but not STS, reduced intrarenal pressure. The effect of NaHS could partially be explained by its activation of the ATP-sensitive potassium channels. In conclusion, treatment with H(2)S attenuates Ang II-associated functional and structural renal deterioration, suggesting that intervention in H(2)S production pathways has potential therapeutic benefit and might be a valuable addition to the already existing antihypertensive and renoprotective therapies.

摘要

高血压和蛋白尿是肾损伤的重要介质。尽管进行了治疗干预,但终末期肾病患者的数量仍在稳步增加。硫化氢(H₂S)是一种内源性产生的气体递质,具有血管舒张、抗炎和抗氧化特性。这些有益特性使H₂S成为高血压肾病药物治疗的一个有吸引力的候选物质。我们研究了H₂S对大鼠血管紧张素II(Ang II)诱导的高血压肾病的保护作用。在输注Ang II的三周期间,用H₂S供体硫氢化钠(NaHS)和主要的H₂S代谢产物硫代硫酸钠(STS)进行治疗,可降低高血压、蛋白尿、氧化应激以及肾功能和结构的恶化。在离体灌注肾实验中,NaHS可降低肾内压,而STS则无此作用。NaHS的作用部分可通过其对ATP敏感性钾通道的激活来解释。总之,H₂S治疗可减轻Ang II相关的肾功能和结构恶化,这表明干预H₂S产生途径具有潜在的治疗益处,可能是现有抗高血压和肾脏保护治疗的有价值补充。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验